title: Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.
abstract: Ivabradine is a new bradycardic agent acting on the I f channels of sinoatrial nodal cells to decrease the rate of diastolic depolarization and thus heart rate. The benefit of ivabradine over other negatively chronotropic agents is its absence of negative inotropy. Effective management of coronary artery disease, in terms of reducing morbidity and mortality, is reliant on controlling heart rate. Ivabradine has been shown to safely and effectively reduce heart rate without compromising cardiac function in patients with coronary artery disease and more recently in patients with heart failure and raised heart rate. Furthermore, ivabradine has been shown to have a favourable side-effect profile compared with alternative bradycardic agents. This article reviews the evidence for ivabradine in coronary artery disease and heart failure and compares its safety with alternative bradycardic agents for these conditions.
authors.affiliation: Advanced Pharmacist Clinical Research, Highland Clinical Research Facility, Centre for Health Science, Old Perth Road, Inverness, IV2 3JH UK.
authors.forename: Gordon F
authors.initials: GF
authors.lastname: Rushworth
authors.affiliation: NHS Highland, Raigmore Hospital, Old Perth Road, Inverness, UK.
authors.forename: Philippe
authors.initials: P
authors.lastname: Lambrakis
authors.affiliation: Consultant Cardiologist, Cardiac Unit, Raigmore Hospital, Inverness IV2 3UJ, UK and University of Stirling, Highland Campus, Old Perth Road, Inverness IV2 3JH, UK.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Leslie
keywords: If channel; If channel inhibitor; coronary artery disease; drug safety; ivabradine
references.citation: Cardiology. 2003;100(3):149-55
references.pmid: 14631136
references.citation: Br J Hosp Med (Lond). 2007 Jun;68(6):321-5
references.pmid: 17639836
references.citation: J Chromatogr B Biomed Sci Appl. 2000 Aug 18;745(2):261-9
references.pmid: 11043745
references.citation: Pharmacol Res. 2006 May;53(5):440-5
references.pmid: 16621590
references.citation: Eur Heart J. 2005 May;26(10):967-74
references.pmid: 15774493
references.citation: Int J Clin Pract. 2006 Feb;60(2):222-8
references.pmid: 16451297
references.citation: Cardiology. 2008;110(4):271-82
references.pmid: 18595216
references.citation: Eur J Heart Fail. 2008 Jun;10(6):550-5
references.pmid: 18486549
references.citation: Cardiology. 2008;110(3):206-8
references.pmid: 18057886
references.citation: Drugs. 2007;67(3):393-405
references.pmid: 17335297
references.citation: J Clin Pharmacol. 2006 Oct;46(10):1195-203
references.pmid: 16988209
references.citation: Adv Cardiol. 2006;43:79-96
references.pmid: 16936474
references.citation: Br J Pharmacol. 1996 Jun;118(4):1051-7
references.pmid: 8799581
references.citation: Coron Artery Dis. 2002 Dec;13(8):427-36
references.pmid: 12544718
references.citation: Pharmacol Res. 2006 May;53(5):435-9
references.pmid: 16644235
references.citation: Drugs R D. 2003;4(2):83-9
references.pmid: 12718562
references.citation: Am J Ther. 2008 Sep-Oct;15(5):461-73
references.pmid: 18806523
references.citation: Lancet. 2010 Sep 11;376(9744):847-9
references.pmid: 20801501
references.citation: Nat Clin Pract Cardiovasc Med. 2004 Dec;1(2):103-9
references.pmid: 16265314
references.citation: Eur J Heart Fail. 2010 Jan;12(1):75-81
references.pmid: 19892778
references.citation: Lancet. 2010 Sep 11;376(9744):875-85
references.pmid: 20801500
references.citation: Lancet. 2010 Sep 11;376(9744):886-94
references.pmid: 20801495
references.citation: Curr Opin Pharmacol. 2007 Apr;7(2):208-13
references.pmid: 17267284
references.citation: Eur Heart J. 2005 Dec;26(23):2529-36
references.pmid: 16214830
references.citation: Am Heart J. 1988 Nov;116(5 Pt 1):1369-73
references.pmid: 3189156
references.citation: Circulation. 2001 Sep 25;104(13):1477-82
references.pmid: 11571239
references.citation: J Gen Physiol. 2002 Jul;120(1):1-13
references.pmid: 12084770
references.citation: Drug Saf. 2008;31(2):95-107
references.pmid: 18217787
references.citation: Cardiology. 2007;108(4):387-96
references.pmid: 17890862
references.citation: Lancet. 2008 Sep 6;372(9641):807-16
references.pmid: 18757088
references.citation: Eur Heart J. 2009 Mar;30(5):540-8
references.pmid: 19136486
references.citation: Clin Pharmacol Ther. 1998 Aug;64(2):192-203
references.pmid: 9728900
references.citation: Br J Clin Pharmacol. 2008 Jul;66(1):96-101
references.pmid: 18341671
references.citation: Circulation. 2003 Feb 18;107(6):817-23
references.pmid: 12591750
references.citation: Drugs. 2004;64(16):1757-65
references.pmid: 15301560
references.citation: Am Heart J. 2006 Nov;152(5):860-6
references.pmid: 17070146
references.citation: Lancet. 2008 Sep 6;372(9641):817-21
references.pmid: 18757091
references.citation: Br J Pharmacol. 2007 Feb;150(4):383-90
references.pmid: 17211458
references.citation: Cardiology. 2009;114(2):116-25
references.pmid: 19468225
references.citation: Circulation. 2004 Apr 6;109(13):1674-9
references.pmid: 14981003
references.citation: J Chromatogr B Biomed Sci Appl. 1998 Nov 20;719(1-2):125-33
references.pmid: 9869372